Cue Biopharma (CUE) vs MindWalk (HYFT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MindWalk (HYFT) has outperformed Cue Biopharma (CUE) over the past year, losing 59.0% versus a loss of 76.8%. Over five years, HYFT leads with a -89.3% price change compared with -98.9% for CUE. Cue Biopharma is the larger company by market cap ($34.7 million vs $32.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | HYFT |
|---|---|---|
| Share price | $4.15 | $0.6844 |
| Market cap | $34.69M | $32.56M |
| 1-day change | -7.78% | -14.27% |
| YTD return | -54.64% | -62.40% |
| 1-year return | -76.75% | -59.02% |
| 5-year return | -98.92% | -89.34% |
| EPS (TTM) | $-27.80 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $27.47M | — |
| Revenue growth (YoY) | +195.75% | — |
| Net income (latest FY) | $-26.60M | — |
| Operating margin | -96.67% | — |
| Net margin | -96.85% | — |
| 52-week high | $45.50 | $2.99 |
| 52-week low | $2.83 | $0.64 |
| Distance from 52-week high | -90.88% | -77.11% |
| Analyst consensus | none | none |
| Avg. price target upside | +2020.48% | +532.67% |
| Average volume | 567.02K | 257.86K |
| Shares outstanding | 8.36M | 47.57M |
| Employees | 29 | 74 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HYFT has outperformed CUE by 17.7 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About MindWalk
HYFT stock →MindWalk Holdings Corp. operates as a bio-native AI company.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
CUE vs HYFT FAQ
Which is bigger, Cue Biopharma or MindWalk?
Cue Biopharma (CUE) is larger, with a market capitalization of $34.69M compared with $32.56M for MindWalk (HYFT).
Which stock has performed better over the past year, CUE or HYFT?
HYFT returned -59.02% over the past 12 months, compared with -76.75% for CUE (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and MindWalk in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.